Norimasa Takeda - Takeda Pharmaceutical Chief Controller

All Insiders . Germany . 
Stock . Takeda Pharmaceutical . Stakeholders . Insider . Norimasa Takeda
TKDA Stock  EUR 12.30  0.10  0.81%   

Insider

Norimasa Takeda is Chief Controller of Takeda Pharmaceutical
Phone81 3 3278 2111
Webhttps://www.takeda.com

Takeda Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Takeda Pharmaceutical has accumulated 4.14 T in total debt with debt to equity ratio (D/E) of 1.0, which is about average as compared to similar companies. Takeda Pharmaceutical has a current ratio of 1.5, which is within standard range for the sector. Debt can assist Takeda Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Takeda Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Takeda Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Takeda to invest in growth at high rates of return. When we think about Takeda Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Shinichi MurayamaHisamitsu Pharmaceutical Co
56
Deborah KochevarElanco Animal Health
62
MichaelBryant HicksElanco Animal Health
44
Shuifa GuiCanSino Biologics
54
Kapila AnandElanco Animal Health
65
John BilbreyElanco Animal Health
63
Constantin FestMerck Company
46
Dean LiMerck Company
N/A
Shuji SugawaraTsumura Co
N/A
Belen MDMerck Company
63
Guoqiang LinHANSOH PHARMAC HD 00001
76
Qiang XuCanSino Biologics
50
Marcus KuhnertMerck Company
55
Xi LuoCanSino Biologics
46
Kai BeckmannMerck Company
58
Chunlin XinCanSino Biologics
N/A
Kyu SaitoHisamitsu Pharmaceutical Co
60
Huihua MaoCanSino Biologics
57
Kirk McDonaldElanco Animal Health
52
Rudi BaoHANSOH PHARMAC HD 00001
55
Ryuji TakasakiTsumura Co
N/A
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. TAKEDA PHARM operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. Takeda Pharmaceutical (TKDA) is traded on Frankfurt Exchange in Germany and employs 47,347 people.

Management Performance

Return On Equity0.0477
Return On Asset0.0247

Takeda Pharmaceutical Leadership Team

Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christophe Weber, CEO Pres
Christopher OReilly, Global Fin
Andrew Plump, Pres Director
Seigo Izumo, Chair Board
Gabriele Ricci, Chief Officer
Salvatore Alesci, Member Policy
Iwaaki Taniguchi, Sr Department
Constantine Saroukos, CFO Director
Haruhiko Hirate, Member Board
Norimasa Takeda, Chief Controller

Takeda Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0477
Return On Asset0.0247
Profit Margin0.07 %
Operating Margin0.13 %
Current Valuation71.66 B
Shares Outstanding3.12 B
Shares Owned By Institutions2.23 %
Price To Earning29.55 X
Price To Book0.95 X
Price To Sales0.01 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Takeda Stock

Takeda Pharmaceutical financial ratios help investors to determine whether Takeda Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Takeda with respect to the benefits of owning Takeda Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY